Medicare AdvantageCoverageMedium impact
MA08.019q, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·Rheumatology, Gastroenterology, Oncology +1 more·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated their policy for intravenous infliximab and related biosimilar medications, effective January 1, 2026. This pharmacy policy change likely affects coverage criteria, prior authorization requirements, or billing procedures for these high-cost specialty infusion drugs.
Action Required
Before January 1, 2026: Billing team must review the complete MA08.019q policy at the provided URL to determine specific changes to infliximab and biosimilar coverage requirements. Update prior authorization workflows, billing procedures, and staff training for Medicare Advantage patients receiving these infusion therapies. Coordinate with clinical staff to ensure compliance with any new documentation or coverage criteria.